Displaying drugs 13051 - 13075 of 15363 in total
INCB13739
INCB13739 is developed as a new treatment for type 2 diabetes.
It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes.
Investigational
Biomed 101
Biomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid. Biomed 101 binds to the leukotriene B4 receptor, but does not affect interleukin-2 antitumor activity.
Investigational
Matched Description: … Biomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma …
Mirostipen
Investigational
Mirococept
Mirococept (APT070) is a complement inhibitor currently under development for treatment of rheumatoid arthritis and I/RI. It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation. It consists...
Investigational
Matched Description: … APT070) is a complement inhibitor currently under development for treatment of rheumatoid arthritis and ... short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and …
AT1391
AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.
Investigational
WL-1002
WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.
Investigational
Actelion-1
Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.
Investigational
Naronapride
Investigational
13-deoxydoxorubicin
GPX-100 is an anthracycline anticancer drug that belongs to the family of drugs called antitumor antibiotics.
Investigational
ABX-PTH
ABX-PTH is a fully human monoclonal antibody generated by Abgenix's technology platform. This drug targets and neutralizes the action of parathyroid hormone (PTH) for the treatment of a secondary hyperparathyroidism.
Investigational
Matched Description: … This drug targets and neutralizes the action of parathyroid hormone (PTH) for the treatment of a secondary …
Linsitinib
An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.
Investigational
Matched Description: … OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and …
Pegpleranib
Investigational
Arverapamil
Investigational
Metampicillin
Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. It is hydrolysed in aqueous solution to form ampicillin. Hydrolysis is rapid under acid conditions like the stomach.
Experimental
3,6-dihydroxy-xanthene-9-propionic acid
Experimental
5-Chloryl-2,4,6-quinazolinetriamine
Experimental
Ganstigmine
Ganstigmine is an orally active, geneserine derived, carbamate-based acetylcholinesterase inhibitor developed for the treatment of Alzheimer's disease.
Investigational
SL017
SL017 formulated as a topical gel, has been combined with a widely available light source for permanent removal of unwanted hair and for treatment of actinic keratosis
Investigational
Matched Description: … gel, has been combined with a widely available light source for permanent removal of unwanted hair and …
Tasquinimod
The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts
Investigational
Matched Description: … anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and …
Nimacimab
Nimacimab is under investigation in clinical trial NCT03261739 (Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)).
Investigational
Matched Description: … Nimacimab is under investigation in clinical trial NCT03261739 (Safety Tolerability, and PK of RYI-018 …
Bamocaftor
Bamocaftor (VX-659) is under investigation in clinical trial NCT03224351 (A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis).
Investigational
Matched Description: … Bamocaftor (VX-659) is under investigation in clinical trial NCT03224351 (A Study Evaluating the Safety and …
Displaying drugs 13051 - 13075 of 15363 in total